Archives: DiagnosticUpdate

Clinical and Molecular Features of HER2-Low Breast Cancer

Overexpression of HER2 contributes to aggressive disease and poor prognosis in patients with HER2-positive breast cancer. This article focuses on recent advancements such as antibody-drug conjugates used in the management of patients with various levels of HER2 expression, including metastatic HER2-low breast cancer.

Next diagnosticupdate in Diagnostic Update